New Molecular Targets in the Therapy of Arthrosis Patients

1. Johnson VL, Hunter DJ. The epidemiology of osteoarthritis. Best Pract Res Clin Rheumatol. 2014 Feb;28(1):5-15.10.1016/j.berh.2014.01.004Search in Google Scholar

2. Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum. 2001 Jun;44(6):1237-47.10.1002/1529-0131(200106)44:6<1237::AID-ART214>3.0.CO;2-FSearch in Google Scholar

3. Bemer P, Leger J, Milin S, Plouzeau C, Valentin AS, Stock N, et al. Histopathological Diagnosis of Prosthetic Joint Infection: Does a Threshold of 23 Neutrophils Do Better than Classification of the Periprosthetic Membrane in a Prospective Multicenter Study? J Clin Microbiol. 2018 Sep;56(9).10.1128/JCM.00536-18Search in Google Scholar

4. Chevalier X, Eymard F, Richette P. Biologic agents in osteoarthritis: hopes and disappointments. Nat Rev Rheumatol. 2013 Jul;9(7):400-10.10.1038/nrrheum.2013.44Search in Google Scholar

5. Goldring SR, Goldring MB. The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clin Orthop Relat Res. 2004 Oct(427 Suppl):S27-36.10.1097/01.blo.0000144854.66565.8fSearch in Google Scholar

6. Blom AB, van Lent PL, Holthuysen AE, van der Kraan PM, Roth J, van Rooijen N, et al. Synovial lining macrophages mediate osteophyte formation during experimental osteoarthritis. Osteoarthritis Cartilage. 2004 Aug;12(8):627-35.10.1016/j.joca.2004.03.003Search in Google Scholar

7. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 2011 Jan;7(1):33-42.10.1038/nrrheum.2010.196Search in Google Scholar

8. Chevalier X, Eymard F. Anti-IL-1 for the treatment of OA: dead or alive? Nat Rev Rheumatol. 2019 Apr;15(4):191-2.10.1038/s41584-019-0185-ySearch in Google Scholar

9. Colombini A, Perucca Orfei C, Kouroupis D, Ragni E, De Luca P, Vigan OM, et al. Mesenchymal stem cells in the treatment of articular cartilage degeneration: New biological insights for an old-timer cell. Cytotherapy. 2019 Dec;21(12):1179-97.10.1016/j.jcyt.2019.10.004Search in Google Scholar

10. Jaswal AP, Bandyopadhyay A. Re-examining osteoarthritis therapy from a developmental biologist’s perspective. Biochem Pharmacol. 2019 Jul;165:17-23.10.1016/j.bcp.2019.03.020Search in Google Scholar

11. Jaswal AP, Ray A, Bandyopadhyay A. Etiology and Treatment of Osteoarthritis: A Developmental Biology Perspective. In: Mukhopadhyay A, editor. Regenerative Medicine: Laboratory to Clinic. Singapore: Springer Singapore; 2017. p. 17-42.10.1007/978-981-10-3701-6_2Search in Google Scholar

12. Scanzello CR. Role of low-grade inflammation in osteoarthritis. Curr Opin Rheumatol. 2017 Jan;29(1):79-85.10.1097/BOR.0000000000000353Search in Google Scholar

13. Kloppenburg M, Ramonda R, Bobacz K, Kwok WY, Elewaut D, Huizinga TWJ, et al. Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018 Dec;77(12):1757-64.10.1136/annrheumdis-2018-213202Search in Google Scholar

14. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012 Apr;64(4):465-74.10.1002/acr.21596Search in Google Scholar

15. McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014 Mar;22(3):363-88.10.1016/j.joca.2014.01.003Search in Google Scholar

16. Parker DA, Scholes C, Neri T. Non-operative treatment options for knee osteoarthritis: current concepts. Journal of ISAKOS: Joint Disorders & Orthopaedic Sports Medicine. 2018;3(5):274-81.10.1136/jisakos-2016-000094Search in Google Scholar

17. Ohtori S, Orita S, Yamauchi K, Eguchi Y, Ochiai N, Kishida S, et al. Efficacy of Direct Injection of Etanercept into Knee Joints for Pain in Moderate and Severe Knee Osteoarthritis. Yonsei Med J. 2015 9/;56(5):1379-83.10.3349/ymj.2015.56.5.1379Search in Google Scholar

18. Aitken D, Laslett LL, Pan F, Haugen IK, Otahal P, Bellamy N, et al. A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis - the HUMOR trial. Osteoarthritis Cartilage. 2018 Jul;26(7):880-7.10.1016/j.joca.2018.02.899Search in Google Scholar

19. Fleischmann RM, Bliddal H, Blanco FJ, Schnitzer TJ, Peterfy C, Chen S, et al. A Phase II Trial of Lutikizumab, an Anti-Interleukin-1alpha/beta Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis. Arthritis Rheumatol. 2019 Jul;71(7):1056-69.10.1002/art.40840Search in Google Scholar

20. Birbara C, Dabezies EJ, Jr., Burr AM, Fountaine RJ, Smith MD, Brown MT, et al. Safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis. J Pain Res. 2018;11:151-64.10.2147/JPR.S135257Search in Google Scholar

21. Dakin P, DiMartino SJ, Gao H, Maloney J, Kivitz AJ, Schnitzer TJ, et al. The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Arthritis Rheumatol. 2019 Nov;71(11):1824-34.10.1002/art.41012Search in Google Scholar